155 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
101 | 20967300 | Vandetanib: An overview of its clinical development in NSCLC and other tumors. | 2010 Sep | 2 |
102 | 19088171 | An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. | 2009 Mar | 2 |
103 | 19220256 | Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. | 2009 Jun | 1 |
104 | 19318229 | Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines. | 2009 Jun | 1 |
105 | 19319137 | Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. | 2009 Apr 21 | 3 |
106 | 19332730 | Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. | 2009 May 20 | 3 |
107 | 19349511 | Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. | 2009 Apr | 4 |
108 | 19362942 | Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy. | 2009 Mar | 1 |
109 | 19409038 | A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. | 2009 Apr | 1 |
110 | 19447868 | Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. | 2009 May 15 | 1 |
111 | 19491268 | Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. | 2009 Jun 15 | 9 |
112 | 19512898 | Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. | 2009 Jul | 2 |
113 | 19687425 | Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. | 2009 Aug | 2 |
114 | 19881951 | The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma. | 2009 Nov | 1 |
115 | 19946413 | DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. | 2009 Sep 21 | 1 |
116 | 17393165 | Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. | 2008 Feb | 15 |
117 | 18177496 | Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib. | 2008 Jan 4 | 1 |
118 | 18248788 | EGFR and VEGFR as potential target for biological therapies in HCC cells. | 2008 Apr 18 | 1 |
119 | 18364248 | Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. | 2008 Jun 28 | 1 |
120 | 18379357 | A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. | 2008 Apr | 2 |
121 | 18381602 | Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. | 2008 Sep | 1 |
122 | 18520295 | Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer. | 2008 Jun | 3 |
123 | 18694994 | Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. | 2008 Aug 15 | 3 |
124 | 18936474 | Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. | 2008 Nov 20 | 1 |
125 | 21479415 | Antitumor activity of ZD6474 in a metastatic orthotopic brain tumor model. | 2008 May-Jun | 3 |
126 | 17203163 | Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. | 2007 Feb | 4 |
127 | 17243944 | Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. | 2007 Feb | 1 |
128 | 17272980 | Combined targeted therapies in non-small cell lung cancer: a winner strategy? | 2007 Mar | 1 |
129 | 17308046 | Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. | 2007 Feb | 3 |
130 | 17414626 | Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. | 2007 Jun | 3 |
131 | 17631646 | Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. | 2007 Nov 1 | 4 |
132 | 17889445 | Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. | 2007 Dec 1 | 2 |
133 | 17912240 | ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein. | 2007 Oct 8 | 1 |
134 | 17975157 | Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. | 2007 Nov 1 | 1 |
135 | 16332356 | ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. | 2006 Feb 14 | 1 |
136 | 16377413 | ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. | 2006 Jan 1 | 3 |
137 | 16688779 | Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. | 2006 Aug | 3 |
138 | 16721126 | Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience. | 2006 Jul | 1 |
139 | 16783964 | ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. | 2006 | 2 |
140 | 16891475 | Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. | 2006 Jul | 2 |
141 | 16937523 | Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects. | 2006 Aug 28 | 1 |
142 | 17136225 | Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. | 2006 Oct | 3 |
143 | 17145834 | Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. | 2006 Dec 1 | 3 |
144 | 17409986 | A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. | 2006 Nov | 2 |
145 | 15709198 | Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. | 2005 Feb 1 | 1 |
146 | 15867237 | A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. | 2005 May 1 | 3 |
147 | 15905307 | Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. | 2005 Aug | 1 |
148 | 15928657 | ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. | 2005 Jun | 3 |
149 | 16061883 | Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. | 2005 Aug 1 | 1 |
150 | 14760102 | Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. | 2004 Jan 15 | 1 |